"Teriparatide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
Descriptor ID |
D019379
|
MeSH Number(s) |
D06.472.699.590.850 D12.644.548.587.850
|
Concept/Terms |
Teriparatide- Teriparatide
- hPTH (1-34)
- Human Parathyroid Hormone (1-34)
|
Below are MeSH descriptors whose meaning is more general than "Teriparatide".
Below are MeSH descriptors whose meaning is more specific than "Teriparatide".
This graph shows the total number of publications written about "Teriparatide" by people in this website by year, and whether "Teriparatide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
2017 | 3 | 4 | 7 |
2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Teriparatide" by people in Profiles.
-
Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance. Calcif Tissue Int. 2021 10; 109(4):351-362.
-
Shoulder periprosthetic fracture in elderly patient: a minimally invasive osteosynthesis and "off-label" treatment with teriparatide. A case report and literature review. J Biol Regul Homeost Agents. 2019 Mar-Apr; 33(2 Suppl. 1):57-62. XIX Congresso Nazionale S.I.C.O.O.P. Societa' Italiana Chirurghi Ortopedici Dell'ospedalita' Privata Accreditata.
-
Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK. Osteoporos Int. 2018 02; 29(2):467-478.
-
Comparison of the effects of once-weekly and once-daily rhPTH (1-34) injections on promoting fracture healing in rodents. J Orthop Res. 2018 04; 36(4):1145-1152.
-
Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study. Clin Interv Aging. 2017; 12:1717-1723.
-
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017 06 06; 166(11):818-839.
-
Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017 Oct; 30(5):677-687.
-
Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos. 2017 Dec; 12(1):39.
-
ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY. Endocr Pract. 2017 Jun; 23(6):657-661.
-
[Effect of drugs for osteoporosis on cardiovascular diseases and effect of cardio vascular drugs on osteoporosis]. Presse Med. 2017 Mar; 46(2 Pt 1):159-164.